Cargando…
Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of different WHO grades and correlates with survival of glioblastoma patients
BACKGROUND: ATF5 suppresses differentiation of neuroprogenitor cells and is overexpressed in glioblastoma (GBM). A reduction of its expression leads to apoptotic GBM cell death. Data on ATF5 expression in astrocytoma WHO grade II (low-grade astrocytoma [LGA]) are scarce and lacking on recurrent GBM....
Autores principales: | Feldheim, Jonas, Kessler, Almuth F, Schmitt, Dominik, Wilczek, Lara, Linsenmann, Thomas, Dahlmann, Mathias, Monoranu, Camelia M, Ernestus, Ralf-Ingo, Hagemann, Carsten, Löhr, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287669/ https://www.ncbi.nlm.nih.gov/pubmed/30584325 http://dx.doi.org/10.2147/OTT.S176549 |
Ejemplares similares
-
Changes of O(6)-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse—A Meta-Analysis Type Literature Review
por: Feldheim, Jonas, et al.
Publicado: (2019) -
Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells
por: Feldheim, Jonas, et al.
Publicado: (2022) -
Monopolar Spindle 1 Kinase (MPS1/TTK) mRNA Expression is Associated with Earlier Development of Clinical Symptoms, Tumor Aggressiveness and Survival of Glioma Patients
por: Kessler, Almuth F., et al.
Publicado: (2020) -
Long-term tumor control of spinal dissemination of cerebellar glioblastoma multiforme by combined adjuvant bevacizumab antibody therapy: a case report
por: Linsenmann, Thomas, et al.
Publicado: (2014) -
Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment Response
por: Hagemann, Carsten, et al.
Publicado: (2019)